Prognostic factors in pancreatic cancer: Highlights from the "2013 ASCO Annual Meeting". Chicago, IL, USA; May 30 - June 4, 2013

Journal of the Pancreas

Volumn 14, Issue 4, 2013, Pages 322-324

  Oikonomopoulos, Georgios Michael ^a   Syrigos, Konstantinos N ^b   Wasif Saif, Muhammad ^c  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

Antigens; CD3; CD4; CD8; Circulating; Equilibrative nucleoside transporter 1; Human; Neoplastic cells; Osteonectin; Pancreatic neoplasms; Predictive value of tests; Prognosis; SPARC protein

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLUOROURACIL; GEMCITABINE; OSTEONECTIN; TRANSCRIPTION FACTOR FOXP3;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESEARCH; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CD4 LYMPHOCYTE COUNT; CIRCULATING TUMOR CELL; DISEASE FREE SURVIVAL; DRUG ACCUMULATION; DRUG TRANSPORT; HUMAN; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; LYMPHOCYTIC INFILTRATION; MEDICAL LITERATURE; METASTASIS; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR INVASION;

EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; HUMANS; NEOPLASTIC CELLS, CIRCULATING; OSTEONECTIN; PANCREATIC NEOPLASMS; PROGNOSIS; T-LYMPHOCYTES;

EID: 84880048404     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Damaraju VL, Damaraju S, Young JD, et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 2003;22:7524-7536
2. Farell J. J., Elsaleh H., Garcia M., et. al Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer. Gastroenterology 2009;136:187-195
3. Jian-Chun Xiao, Tai-Ping Zhang et al. hENT1 predicts the Asian patient response to Gemcitabine-based chemotherapy in Pancreatic Cancer. Hepatogastroenterology 2013;60(122):Ahead of print
4. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007;6:1186-97
5. Chu GC, Kimmelman AC, Hezel AF, DePinho RA. Stromal biology of pancreatic cancer. J Cell Biochem 2007;101:887-907
6. Manuel Hidalgo and Daniel D. Von Hoff. Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas. Clin Cancer Res 2012;18:4249-4256
7. Negin B. P., Meropol N. J., Alpaugh R. K., et. al Characterization and prognostic significance of circulating tumor cells in the peripheral blood of patients with metastatic pancreatic cancer. Journal of Clinical Oncology, 2010 Vol 28, No 15_suppl 2010: 4127
8. Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Itoh T, Morikawa T, Okushiba S, Kondo S, Katoh H. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumorinfiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004;28:e26-3
9. Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006;12:5423-34.
10. Neoptolemos J. P., Greenhalf W., Ghaneh P, et al. HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials. J Clin Oncol 31, 2013 (suppl; abstr 4006)
11. Sinn M., Sinn VB., Striefer JK., et. al SPARC in pancreatic cancer: Results from the CONKO-001 study. J Clin Oncol 31, 2013 (suppl; abstr 4016)
12. Huhuet F., Bidard FC., Louvet C, et al. Circulating tumor cells in locally advanced pancreatic adenocarcinoma. The ancillary study Circe-07 of the LAP-07 trial J Clin Oncol 31,2013 (suppl abstr 4046)
13. Turcotte S., McNikoll Y., Soucy G., et al. Prognostic value of an immune score combining intra-and peritumoral T-cell subset density in patients with pancreatic adenocarcinoma J Clin. Oncol 31, 2013 (suppl; abstr 4060)
14. Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:319-25
15. Arnold SA, Rivera LB, Miller AF, Carbon JG, Dineen SP, Xie Y, et al. Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech 2010;3:57-72
16. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29:4548-54
17. Toshio K, Takao I, Atshushi S et al. Detection of circulating tumor cells in patients with pancreatic cancer: A preliminary result J. Hepatobilliary Pancr Surg. 2008;15:189-195